Bayer Aktiengesellschaft

Bayer Pharma Aktiengesellschaft

Deutsches Krebsforschungszentrum

Deutsches Krebsforschungszentrum Heidelberg

Rafael Carretero

Ulf Bömer

Hans Briem

Benjamin Bader

Detlef Stöckigt

Michael Platten

Lars Röse

Ilona Gutcher

Christina Kober

Ludwig Zorn

Ulrike Röhn

Bernd Buchmann

Norbert Schmees

Roland Neuhaus

Olaf Panknin

Kirstin Petersen

Sandra Berndt

Horst Irlbacher

Rienk Offringa

Manfred Husemann

Jeffrey Stuart Mowat

Nuria Aiguabella Font

Gabriele Leder

Robin Michael Meier

Anders Roland Friberg

The present invention covers 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamide compounds of general formula (1): in which X, R, R, R, Rand Rare as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.

2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer

The present invention covers 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyri-dazine-4-carboxamide compounds of general formula (I): in which R, R, R, R, R, X, Y and Z are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients. 

3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides

Disclosed are compounds of general formula (I): wherein R, R, A, X, Y and Z are as defined herein, methods of preparing the compounds, intermediate compounds useful for preparing the compounds, pharmaceutical compositions and combinations comprising the compounds and the use of the compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.

Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides

The present invention relates to protein-inhibitory substituted pyrrolopyridine derivatives of formula (I), in which A, X, R, R, R, R, R, Rand Rare as defined herein, to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compounds, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for neoplastic disorders, respectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, as a sole agent or in combination with other active ingredients. The present invention further relates to the use, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of protein inhibitors in benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, in neurodegenerative disorders, in inflammatory disorders, in atherosclerotic disorders and in male fertility control. 

Substituted pyrrolopyridine-derivatives

Growing community of inventors

Heidelberg, Germany

Rafael Carretero